GeneHealth - Your precision medicine

Catecholaminergic Polymorphic Ventricular Tachycardia

Disease Details

Family Health Simplified

Buy Membership

Description: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare genetic disorder characterized by stress-induced abnormal heart rhythms that can lead to fainting, seizures, or sudden cardiac death.
Type: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited cardiac condition typically transmitted in an autosomal dominant or autosomal recessive manner.
Signs And Symptoms: Although individuals with CPVT may not experience any symptoms, the most commonly reported symptoms are blackouts or sudden loss of consciousness, referred to as syncope. These blackouts often occur during exercise or as a response to emotional stress—situations in which chemical messengers known as catecholamines, such as adrenaline, are released within the body. Blackouts may be misinterpreted as being caused by simple faints or epilepsy, often leading to delays in reaching the correct diagnosis. In a third of those affected, the first manifestation of the disease may be cardiac arrest, potentially leading to sudden death. This can occur in very young children, presenting as sudden infant death syndrome or 'cot death'. Approximately 30% of those with CPVT will have a family member who has experienced blackouts, seizures, or sudden death in response to exercise or stress.In those with CPVT, catecholamine release can lead to an abnormal heart rhythm or arrhythmia known as ventricular tachycardia. The ventricular tachycardia may take a characteristic form known as bidirectional ventricular tachycardia. This form of ventricular tachycardia occurs relatively infrequently, but if seen is suggestive of an underlying diagnosis of CPVT or the related condition Andersen-Tawil syndrome. These ventricular arrhythmias in some cases terminate by themselves, causing a blackout from which the person then recovers. However, if the abnormal heart rhythm continues, it can degenerate into a more dangerous arrhythmia known as ventricular fibrillation causing a cardiac arrest and, if untreated, sudden death.There are typically very few abnormal signs on clinical examination in persons with CPVT. However, those with CPVT may develop a less serious heart rhythm disturbance called atrial fibrillation, which can be detected on examination as an irregular pulse. Furthermore, approximately 20% of those with CPVT have a slow resting heart rate known as a sinus bradycardia.
Prognosis: A significant proportion of those with CPVT will experience a life-threatening abnormal heart rhythm, with estimates of this risk ranging from 13 to 20% over the course of 7–8 years. Life-threatening arrhythmias are more likely to occur if CPVT has been diagnosed in childhood, if a person with CPVT does not take beta blockers, and if arrhythmias occur on exercise testing despite taking beta blockers.During treatment with nadolol, the preferred beta blocker for the treatment of CPVT, event rates have been estimated to be 0.8% per year. In patients treated with beta blockers, life-threatening arrhythmias are more likely if a person had already survived a cardiac arrest, had a syncope, or are carriers of disease-causing mutations affecting the highly conserved terminal portion of RYR2 gene, called the C-terminal domain (amino acids 4889–4969).
Onset: Catecholaminergic polymorphic ventricular tachycardia (CPVT) typically has an onset in childhood or adolescence. It can be triggered by physical activity or emotional stress, leading to abnormal heart rhythms. Many individuals with CPVT may experience symptoms such as palpitations, fainting (syncope), or even sudden cardiac arrest during these trigger events.
Prevalence: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare genetic condition. Its prevalence is not definitively known, but it is estimated to affect approximately 1 in 10,000 people.
Epidemiology: CPVT is estimated to affect 1 in 10,000 people. Symptoms from CPVT are typically first seen in the first or second decade of life, and more than 60% of affected individuals experience their first episode of syncope or cardiac arrest by age 20. Syncope during exercise or strong emotion should be considered a red flag, as it is a characteristic of the disease. Lastly, a small number of patients may present later in life, and genetic testing in these patients frequently fails to identify a causative gene.
Intractability: Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) is considered a challenging disease to manage, but it is not entirely intractable. With proper diagnosis and treatment, including the use of medications such as beta-blockers and lifestyle modifications, many patients can manage their symptoms and reduce the risk of life-threatening arrhythmias. In some cases, an implantable cardioverter-defibrillator (ICD) may be recommended. However, the condition requires careful and continuous management by a specialist.
Disease Severity: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a severe and potentially life-threatening arrhythmia disorder. Triggered by physical or emotional stress, CPVT can lead to rapid and irregular heartbeats, causing fainting, seizures, or sudden cardiac arrest if untreated.

Management typically includes lifestyle modifications to avoid triggers, beta-blocker medications, and sometimes implantable cardioverter-defibrillators (ICDs) for severe cases. Regular follow-up with a cardiologist familiar with CPVT is crucial for optimal management.
Healthcare Professionals: Disease Ontology ID - DOID:0060674
Pathophysiology: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a genetic disorder characterized by abnormal heart rhythms that can occur in response to physical activity or emotional stress. The primary pathophysiological mechanism involves mutations in genes that encode proteins responsible for regulating calcium handling in the heart muscle cells, such as the ryanodine receptor 2 (RYR2) or calsequestrin 2 (CASQ2) genes. These mutations lead to abnormal calcium release from the sarcoplasmic reticulum, causing delayed afterdepolarizations that can trigger life-threatening arrhythmias. CPVT typically manifests as bidirectional or polymorphic ventricular tachycardia during periods of increased adrenergic stimulation.
Carrier Status: Carrier status for catecholaminergic polymorphic ventricular tachycardia (CPVT) typically refers to individuals who have a mutation in one of the genes associated with the condition but do not show symptoms. CPVT is primarily inherited in an autosomal dominant pattern, meaning that having one mutated copy of the gene can predispose an individual to the condition. However, carriers might remain asymptomatic and not develop the full-blown disease. In rarer cases, CPVT can be inherited in an autosomal recessive manner, where two mutated copies of the gene are required for the condition to manifest. Genetic testing can identify carrier status.
Mechanism: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a genetic arrhythmia syndrome precipitated by physical or emotional stress. The primary mechanism involves dysregulation of calcium handling within cardiac cells. During stress, the release of catecholamines leads to an increased intracellular calcium load, triggering abnormal electrical activity in the heart.

At the molecular level, mutations in the RYR2 gene, which encodes the ryanodine receptor, or the CASQ2 gene, which encodes calsequestrin, are the most common causes. These mutations disrupt the normal function of the calcium release channel in the sarcoplasmic reticulum, resulting in excessive calcium release. This excess calcium leads to delayed afterdepolarizations (DADs) and subsequent triggered activity, causing the characteristic polymorphic ventricular tachycardia observed in CPVT.
Treatment: Treatments for CPVT aim to prevent lethal abnormal heart rhythms from occurring, and to rapidly restore a normal rhythm if they do occur. As the arrhythmias in CPVT generally occur at times when the heart is exposed to high levels of adrenaline or other similar chemical messengers (catecholamines), many treatments for CPVT aim to lower the levels of catecholamines the heart is exposed to or block their effects on the heart.The first-line treatment for those with CPVT involves lifestyle advice. This includes avoiding competitive sports, very strenuous exercise and highly stressful environments, as high levels of adrenaline can occur in these settings, which can provoke arrhythmias.
Compassionate Use Treatment: For Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), compassionate use treatments and off-label or experimental treatments are generally considered when standard therapies are ineffective or unsuitable. Some potential options include:

1. **Flecainide**: Often used off-label to reduce the occurrence of arrhythmias by blocking sodium channels.
2. **Propranolol and Nadolol**: Beta-blockers commonly used, but at higher than typical doses or combined with other medications for enhanced effect.
3. **Ivabradine**: An off-label treatment that reduces heart rate without affecting blood pressure.
4. **Gene Therapy**: Experimental approaches are being explored to correct the underlying genetic causes.
5. **Implantable Cardioverter-Defibrillators (ICDs)**: Though not a medication, this device can be used in combination with medications to prevent sudden cardiac death.

These treatments are typically considered in specialized centers under strict medical supervision due to potential side effects and the need for precise dosing and monitoring.
Lifestyle Recommendations: For catecholaminergic polymorphic ventricular tachycardia (CPVT), lifestyle recommendations typically include:

1. **Avoiding Triggers**: Minimize physical and emotional stress, which can trigger arrhythmias.
2. **Regular Monitoring**: Regular follow-up with a cardiologist to monitor the condition.
3. **Medication Adherence**: Strict adherence to prescribed beta-blockers or other medications to manage symptoms.
4. **Exercise Limitations**: Avoid high-intensity sports or exercise unless specifically cleared by a healthcare provider.
5. **Emergency Planning**: Having an emergency action plan, including access to an automatic external defibrillator (AED), if recommended.
6. **Family Screening**: Family members may need to be screened, as CPVT can run in families.

Consulting with a healthcare provider for personalized advice is essential.
Medication: Several medications can be useful for those with CPVT. The mainstays of treatment are beta blockers, which block the effects of adrenaline and other catecholamines on the heart, reducing the chance of abnormal heart rhythms developing. Of all the beta blockers, nadolol has been proven to be the most effective for treating CPVT. This drug lowers the heart rate to a greater extent than other beta blockers and only needs to be taken once daily, reducing the risk of missed doses. Nadolol may be difficult to obtain and is not available in all countries, and an alternative beta blocker suitable for use in CPVT may be propranolol, which however has a more complex dosing regimen. Recently published data suggest that the use of selective beta blockers, such as atenolol, bisoprolol, or metoprolol, is associated with very high treatment failure rates.Flecainide is a class 1c antiarrhythmic drug that is recommended for those with CPVT who experience abnormal heart rhythms despite taking a beta blocker. Flecainide reduces the risk of arrhythmias in those with CPVT, but it remains uncertain how Flecainide achieves this. Some have suggested that Flecainide directly interacts with the cardiac ryanodine receptor, which is frequently abnormal in those with CPVT, while other suggest that the anti-arrhythmic effects of Flecainide rely entirely on its sodium channel blocking effects.Verapamil is a calcium channel antagonist that, when combined with a beta blocker, may reduce the risk of arrhythmias in patients with CPVT. Propafenone is another antiarrhythmic that may reduce the risk of arrhythmias, potentially through direct effects on the ryanodine receptor.
Repurposable Drugs: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a genetic condition characterized by abnormal heart rhythms. There are some existing medications that have been explored for repurposing to manage CPVT symptoms:

1. **Beta-blockers** (e.g., nadolol, propranolol) - These are often the first line of treatment as they help to control heart rate and reduce the risk of arrhythmias.

2. **Flecainide** - This antiarrhythmic drug can be used alongside beta-blockers to further reduce arrhythmia risk.

3. **Calcium channel blockers** (e.g., verapamil) - These may be considered when beta-blockers are not effective or tolerated.

These medications are repurposed from their original indications to manage the symptoms and reduce the risk of life-threatening arrhythmias in CPVT patients. However, it's essential for treatment to be guided by a specialist in cardiovascular diseases or a geneticist due to the complex nature of CPVT and the potential need for combination therapy or other interventions.
Metabolites: Catecholaminergic polymorphic ventricular tachycardia (CPVT) primarily involves disruptions in calcium handling within cardiomyocytes, which can lead to ventricular arrhythmias. While CPVT does not have well-known specific metabolites associated directly with it, it involves the dysregulation of catecholamines (like adrenaline and noradrenaline) that can trigger these arrhythmic events. Elevated levels of these catecholamines during stress or exercise are typically the proximate factors in arrhythmia onset for individuals with CPVT.
Nutraceuticals: Nutraceuticals are not a primary treatment for catecholaminergic polymorphic ventricular tachycardia (CPVT). Management of CPVT typically involves medications such as beta-blockers and lifestyle modifications to reduce stress and physical exertion. Implantable cardioverter-defibrillators (ICDs) may be considered in high-risk patients. Nutraceuticals have not been shown to be effective in managing or treating CPVT.
Peptides: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a genetic disorder characterized by abnormal heart rhythms, specifically during physical activity or emotional stress. Peptides are short chains of amino acids, but in the context of CPVT, they are not typically central to its pathology or treatment. The condition is more directly related to dysfunctional cardiac ion channels and calcium handling, often due to mutations in genes such as RYR2 or CASQ2.

Nan (nanoseconds) usually refers to a time measurement in scientific contexts and does not have a direct relation to CPVT. If you meant nanotechnology, it is not currently a standard approach in the diagnosis or treatment of CPVT.